Please use a minimum of three unique search words
Our search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Lyumjev ® ▼ (insulin lispro)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
Lyumjev® ▼ (insulin lispro): Citrate and Effect as Excipient
Citrate is an excipient in Lyumjev formulation that acts to increase vascular permeability.
Sodium citrate is an excipient that acts to increase vascular permeability, resulting in the accelerated absorption of insulin lispro.1-4
Citrate is a common GRAS ingredient used in many pharmaceutical formulations.5-7
1. Leohr J, Pratt EJ, Heilmann C, et al. A novel insulin lispro formulation containing citrate and treprostinil demonstrates faster absorption and onset of insulin action in healthy subjects [abstract]. Diabetes. 2017;66(suppl 1):A253. American Diabetes Association abstract 976‑P. http://dx.doi.org/10.2337/db17-890-1488
2. Michael MD, Zhang C, Siesky AM, et al. Exploration of the Mechanism of Accelerated Absorption for a Novel Insulin Lispro Formulation [abstract]. Diabetes. 2017;66(suppl 1):A250. http://dx.doi.org/10.2337/db17-890-1488
5. US Food and Drug Administration (FDA). Generally Recognized as Safe (GRAS). Updated September 6, 2019. Accessed July 3, 2020. https://www.fda.gov/food/ingredientspackaginglabeling/gras/
6. US Food and Drug Administration (FDA). Select Committee on GRAS Substances (SCOGS) Opinion: Citric acid, Citrates. Updated September 24, 2015. Accessed July 3, 2020. http://wayback.archive-it.org/7993/20171031063409/https://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCOGS/ucm260861.htm
7. US Food and Drug Administration (FDA). CFR - Code of Federal Regulations Title 21. US Food and Drug Administration. Updated April 1, 2019. Accessed July 3, 2020. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=184.1751
GRAS = generally recognized as safe
URLi = ultra rapid lispro
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Date of Last Review: 06 August 2019